Suppr超能文献

秘鲁利马慢性肾病患者延缓透析进展和死亡策略的成本效益分析。

Cost-effectiveness analysis of a strategy to delay progression to dialysis and death among chronic kidney disease patients in Lima, Peru.

作者信息

Saldarriaga E M, Bravo-Zúñiga J, Hurtado-Roca Y, Suarez V

机构信息

Instituto de Evaluación de Tecnologías en Salud E Investigación (IETSI), EsSalud, Av. Arenales 1302, office 310, Lima, Perú.

The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, USA.

出版信息

Cost Eff Resour Alloc. 2021 Oct 10;19(1):70. doi: 10.1186/s12962-021-00317-0.

Abstract

BACKGROUND

The Renal Health Program (RHP) was implemented in 2013 as a secondary prevention strategy to reduce the incidence of patients initiating dialysis and overall mortality. A previous study found that adherent patients have 58% protection against progression to dialysis compared to non-adherent. The main objective of the study was to estimate the lifetime economic and health consequences of the RHP intervention to determine its cost-effectiveness in comparison with usual care.

METHODS

We use a Markov model of three health stages to simulate disease progression among chronic kidney disease patients in Lima, Peru. The simulation time-horizon was 30 years to capture the lifetime cost and health consequences comparing the RHP to usual care. Costs were estimated from the payer perspective using institutional data. Health outcomes included years lived free of dialysis (YL) and quality adjusted life years (QALY). We conducted a probabilistic sensitivity analysis (PSA) to assess the robustness of our estimates against parameter uncertainty.

RESULTS

We found that the RHP was dominant-cost-saving and more effective-compared to usual care. The RHP was 783USD cheaper than the standard of care and created 0.04 additional QALYs, per person. The Incremental Cost-Effectiveness Ratio (ICER) showed a cost per QALY gained of $21,660USD. In the PSA the RHP was dominant in 996 out of 1000 evaluated scenarios.

CONCLUSIONS

The RHP was cheaper than the standard of care and more effective due to a reduction in the incidence of patients progressing to dialysis, which is a very expensive treatment and many times inaccessible. We aim these results to help in the decision-making process of scaling-up and investment of similar strategies in Peru. Our results help to increase the evidence in Latin America where there is a lack of information in the long-term consequences of clinical-management-based prevention strategies for CKD patients.

摘要

背景

肾脏健康计划(RHP)于2013年实施,作为一项二级预防策略,以降低开始透析的患者发生率和总体死亡率。先前的一项研究发现,与未坚持治疗的患者相比,坚持治疗的患者进展为透析的风险降低了58%。该研究的主要目的是评估RHP干预措施的终身经济和健康后果,以确定其与常规治疗相比的成本效益。

方法

我们使用一个三健康阶段的马尔可夫模型来模拟秘鲁利马慢性肾病患者的疾病进展。模拟时间范围为30年,以比较RHP与常规治疗的终身成本和健康后果。成本是从支付者的角度使用机构数据进行估算的。健康结果包括无透析生存年数(YL)和质量调整生命年(QALY)。我们进行了概率敏感性分析(PSA),以评估我们的估计对参数不确定性的稳健性。

结果

我们发现,与常规治疗相比,RHP具有成本节约优势且更有效。RHP比标准治疗便宜783美元,每人增加0.04个QALY。增量成本效益比(ICER)显示,每获得一个QALY的成本为21,660美元。在PSA中,RHP在1000个评估情景中的996个情景中占主导地位。

结论

RHP比标准治疗更便宜且更有效,因为进展为透析的患者发生率降低,而透析是一种非常昂贵且很多时候无法获得的治疗。我们希望这些结果有助于秘鲁扩大和投资类似策略的决策过程。我们的结果有助于增加拉丁美洲的证据,该地区缺乏基于临床管理的CKD患者预防策略长期后果的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad37/8504107/423b1edc09b9/12962_2021_317_Fig3_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验